年轻高危弥漫大B淋巴瘤诊治进展-王晓东.pptVIP

那根据最新的ESMO指南，对于年龄小于60岁的AAIPI大于等于2分的中高危和高危患者的治疗方案，目前尚未达成共识，那比较常用的就是8RCHOP21或者14，或者6-8RCHOEP/ACVBP，或者大剂量化疗联合自体干细胞移植。那这些都是基于临床经验或者小样本的临床研究得来的，目前对于这些治疗方案还是比较有争议的 * Hans根据CD10、BCL-6及IRF4/MUM1三者表达情况将弥漫性大B细胞淋巴瘤病人划分为长期和短期生存者，即所谓“Hans分类” Data regarding 219 patients (125 males, 94 females; median age, 61 years) consecutively diagnosed with de novo DLBCL between 2002 and 2007 11 patients who received no treatment were excluded from the survival analyses. All the remaining patients received immunochemotherapy, including adriamycin-containing regimens in 196 cases (185 received R-CHOP, and 11 patients rec